Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CCR9 | P51686 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21354979 | 0.83 | KLKB1 (0.47) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL10003895 | 0.78 | NOD2 (0.48) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL30316927 | 0.75 | NOD1 (0.48) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL10003163 | 0.75 | NOD1 (0.53) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL10002626 | 0.75 | NOD1 (0.61) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL14627380 | 0.74 | NOD1 (0.78) | NOD1NOD2LMNAALDH1A1HTT | |
| SCHEMBL10003206 | 0.72 | NOD1 (0.58) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL23147752 | 0.72 | NOD2 (0.47) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL10002821 | 0.71 | NOD1 (0.57) | NOD1NOD2LMNAKDM4EL3MBTL1 | |
| SCHEMBL10003470 | 0.71 | NOD2 (0.51) | NOD1NOD2LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | NOD1 3068/4885NOD2 4456/4885LMNA 1722/4885 |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | NOD1 3068/4885NOD2 4456/4885LMNA 1722/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | NOD1 3068/4885NOD2 4456/4885LMNA 1722/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | NOD1 3068/4885NOD2 4456/4885LMNA 1722/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | NOD1 3068/4885NOD2 4456/4885LMNA 1722/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | NOD1 3068/4885NOD2 4456/4885LMNA 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.